Download PDF
Semin Respir Crit Care Med 2004; 25(3): 337-344
DOI: 10.1055/s-2004-829505
Published by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Tuberculosis and HIV/AIDS: Epidemiological and Clinical Aspects (World Perspective)

Naomi Bock1 , Lee B. Reichman2
  • 1Global AIDS Program, Centers for Disease Control and Prevention, Atlanta, Georgia
  • 2New Jersey Medical School National Tuberculosis Center, Newark, New Jersey
Further Information

Publication History

Publication Date:
29 June 2004 (online)

    Permissions and Reprints

Human immunodeficiency virus (HIV) infection is the most powerful known risk factor for progression from latent infection with Mycobacterium tuberculosis to active tuberculosis (TB) disease. The worldwide HIV epidemic has affected TB in every aspect: immunopathology, epidemiology, diagnosis, treatment, and prevention. Of the 42 million people infected with HIV worldwide, more than a quarter of them are also infected with TB, and most live in countries with limited resources for health care in Africa and Asia. This chapter emphasizes HIV-associated TB in resource-limited settings. TB-infected persons with HIV-associated immunosuppression progress to TB disease at a rate of up to 10% per year. Standard TB diagnostic tools have diminished sensitivity in HIV co-infected cases. Standard TB treatment regimens may be less effective, particularly those that do not use a rifamycin throughout. Treatment is further complicated by toxicity, malabsorption, drug-drug interactions and immune reconstitution paradoxical reactions. TB control in the United States was destabilized in part by the HIV epidemic in the early 1990s; massive political will and resources were required to rebuild the public health infrastructure. Africa, Asia, and potentially the former Soviet Union are facing even greater destabilization of TB control due to the dual burden of disease and limited resources. An international response has been initiated but will require even greater political will and resources.

KEYWORDS

Mycobacterium tuberculosis - human immunodeficiency virus

REFERENCES

  • 1 Corbett E Z, Watt C J, Walker N et al.. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.  Arch Intern Med. 2003;  163 1009-1021
    CrossrefPubMedGoogle Scholar
  • 2 Rana F S, Hawken M P, Mwachari C et al.. Autopsy study of HIV-1 positive and HIV-1 negative adult medical patients in Nairobi, Kenya.  J Acquir Immune Defic Syndr. 2000;  24 23-29
    CrossrefPubMedGoogle Scholar
  • 3 Raviglione M C, Harries A D, Msiska R, Wilkinson D, Nunn P. Tuberculosis and HIV: current status in Africa.  AIDS. 1997;  11(suppl B) S115-S123
    PubMedGoogle Scholar
  • 4 Godrey-Faussett P, Ayles H. Can we control tuberculosis in high HIV prevalence settings?.  Tuberculosis. 2003;  83 68-76
    CrossrefPubMedGoogle Scholar
  • 5 World Health Organization .Guidelines for Implementing Collaborative TB and HIV Programme Activities. Geneva; World Health Organization 2003
    Google Scholar
  • 6 Tracevska T, Jansone I, Baumanis V, Marga O, Lillebaek T. Prevalence of Beijing genotype in Latvian multidrug-resistant Mycobacterium tuberculosis isolates.  Int J Tuberc Lung Dis. 2003;  7 1097-1103
    PubMedGoogle Scholar
  • 7 Reichman L B, Tanne J H. Timebomb: The Global Epidemic of Multi-Drug-Resistant Tuberculosis. New York; McGraw-Hill 2002
    Google Scholar
  • 8 Cantwell M F, Snider D E, Cauthen G M, Onorato I M. Epidemiology of tuberculosis in the United States, 1985 through 1992.  JAMA. 1994;  272 535-539
    PubMedGoogle Scholar
  • 9 Bloom B R, Murray C JL. Tuberculosis: commentary on a reemergent killer.  Science. 1992;  257 1055-1064
    PubMedGoogle Scholar
  • 10 CDC .HIV/AIDS Surveillance Report. 2002 14: 17
    Google Scholar
  • 11 Bennett D E, Courval J M, Onorato I M et al.. Prevalence of TB infection in the US population. Abstract #67921. American Public Health Association, 131st Annual Meeting, November 15-19 2003 American Public Health Association Washington, DC;
    Google Scholar
  • 12 CDC .Reported Tuberculosis in the United States, 2001. Atlanta; U.S. Department of Health and Human Services 2002
    Google Scholar
  • 13 Frieden T R, Fujiwara P I, Washko R M, Hamburg M A. Tuberculosis in New York City: turning the tide.  N Engl J Med. 1995;  333 229-233
    CrossrefPubMedGoogle Scholar
  • 14 Schluger N W, Rom W N. The host immune response to tuberculosis.  Am J Respir Crit Care Med. 1998;  157 679-691
    PubMedGoogle Scholar
  • 15 Schluger N W, Perez D, Lui Y M. Reconstitution of immune responses to tuberculosis in patients with HIV infection who receive antiretroviral therapy.  Chest. 2002;  122 597-602
    CrossrefPubMedGoogle Scholar
  • 16 Daley C L, Small P M, Schecter G F et al.. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms.  N Engl J Med. 1992;  326 231-235
    CrossrefPubMedGoogle Scholar
  • 17 Sonnenberg P, Murray J, Glynn J R, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers.  Lancet. 2001;  358 1678-1693
    PubMedGoogle Scholar
  • 18 Fitzpatrick L K, Okwera A, Mugerwa R, Ridzon R, Ehiner J, Onorato I. An investigation of suspected exogenous reinfection in tuberculosis patients in Kampal, Uganda.  Int J Tuberc Lung Dis. 2002;  6 550-552
    PubMedGoogle Scholar
  • 19 Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study.  Lancet. 2002;  359 2059-2064
    CrossrefPubMedGoogle Scholar
  • 20 Ledergerber B, Egger M, Erard V et al.. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV cohort study.  JAMA. 1999;  282 2220-2226
    CrossrefPubMedGoogle Scholar
  • 21 Goletti D, Weissman D, Jackson R W et al.. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation.  J Immunol. 1996;  157 1271-1278
    PubMedGoogle Scholar
  • 22 Whalen C, Horsburgh R, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis.  Am J Crit Care Med. 1995;  151 129-135
    PubMedGoogle Scholar
  • 23 Leroy V, Sami R L, Dupon M et al.. Progression of human immunodeficiency virus infection in patients with tuberculosis disease: a cohort study in Bordeaux, France 1988-1994.  Am J Epidemiol. 1997;  145 293-300
    PubMedGoogle Scholar
  • 24 Petruckevitch A, Del Amo J, Phillips A N et al.. Disease progression and survival following specific AIDS-defining conditions: a retrospective cohort study of 2048 HIV-infected persons in London.  AIDS. 1998;  12 1007-1013
    CrossrefPubMedGoogle Scholar
  • 25 Mocroft A J, Lundgren J D, Monforte A D et al.. Survival of AIDS patients according to type of AIDS-defining event.  Int J Epidemiol. 1997;  26 400-407
    CrossrefPubMedGoogle Scholar
  • 26 Bucher H C, Griffith L E, Guyatt G H et al.. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials.  AIDS. 1999;  13 501-507
    CrossrefPubMedGoogle Scholar
  • 27 Del Amo J, Malin A S, Pozniak A, De Cock K M. Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology.  AIDS. 1999;  13 1151-1158
    PubMedGoogle Scholar
  • 28 Jones B E, Young S MM, Antoniskis D et al.. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection.  Am Rev Respir Dis. 1993;  148 1292-1297
    CrossrefPubMedGoogle Scholar
  • 29 Ackah A N, Coulibaly D, Digbeu H et al.. Response to treatment, mortality and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire.  Lancet. 1995;  345 607-610
    CrossrefPubMedGoogle Scholar
  • 30 Elliott A M, Halwiindi B, Hayes R J et al.. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia.  J Trop Med Hyg. 1993;  96 1-11
    PubMedGoogle Scholar
  • 31 Theuer C P, Hopewell P C, Elias D et al.. Human immunodeficiency virus infection in tuberculosis patients.  J Infect Dis. 1990;  162 8-12
    CrossrefPubMedGoogle Scholar
  • 32 Harries A D. Tuberculosis in Africa: clinical presentation and management.  Pharmacol Ther. 1996;  73 1-50
    PubMedGoogle Scholar
  • 33 De Cock K M, Soro B, Coulibaly I M, Lucas S B. Tuberculosis and HIV infection in sub-Saharan Africa.  JAMA. 1992;  268 1581-1587
    CrossrefPubMedGoogle Scholar
  • 34 Toman K. Tuberculosis Case-Finding and World Health Organization, Chemotherapy: Questions and Answers. Geneva; World Health Organization 1979
    Google Scholar
  • 35 Jones B E, Ryu R, Yang Z et al.. Chest radiographic findings in patients with tuberculosis with recent or remote infection.  Am J Respir Crit Care Med. 1997;  157 1270-1273
    PubMedGoogle Scholar
  • 36 Greenberg S D, Frager D, Suster B et al.. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance).  Radiology. 1994;  193 115-119
    CrossrefPubMedGoogle Scholar
  • 37 Pitchenik A E, Rubinson H A. The radiographic appearance of tuberculosis in patients with the acquired immune deficiency syndrome (AIDS) and pre-AIDS.  Am Rev Respir Dis. 1985;  131 393-396
    PubMedGoogle Scholar
  • 38 Perlman D C, el-Sadr W M, Nelson E T et al.. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression.  Clin Infect Dis. 1997;  25 242-246
    CrossrefPubMedGoogle Scholar
  • 39 Graf P. Tuberculosis control in high-prevalence countries. In: Davies PDO Clinical Tuberculosis 1994. London; Chapman & Hall 1994: 325-339
    Google Scholar
  • 40 Foulds J, O'Brien R. New tools for the diagnosis of tuberculosis: the perspective of developing countries.  Int J Tuberc Lung Dis. 1998;  2 778-783
    PubMedGoogle Scholar
  • 41 Havlir D V, Barnes P F. Current concepts: tuberculosis in patients with human immunodeficiency virus infection.  N Engl J Med. 1999;  340 367-373
    CrossrefPubMedGoogle Scholar
  • 42 Chaisson R E, Clermont H C, Holt E A et al.. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection.  Am J Respir Crit Care Med. 1996;  154 1034-1038
    PubMedGoogle Scholar
  • 43 Perriens J H, St. Louis M E, Mukadi Y B et al.. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months.  N Engl J Med. 1995;  332 779-784
    CrossrefPubMedGoogle Scholar
  • 44 ATS/CDC/IDSA . Treatment of tuberculosis.  MMWR Morb Mortal Wkly Rep. 2003;  52(RR11) 1-77
    PubMedGoogle Scholar
  • 45 CDC . Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.  MMWR Morb Mortal Wkly Rep. 2002;  51 214-215
    PubMedGoogle Scholar
  • 46 El-Sadr W M, Perlman D C, Matts J P et al.. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG).  Clin Infect Dis. 1998;  26 1148-1158
    PubMedGoogle Scholar
  • 47 Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.  Lancet. 1999;  353 1843-1847
    CrossrefPubMedGoogle Scholar
  • 48 Narita M, Ashkin D, Hollender E S, Pitchenik A E. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.  Am J Respir Crit Care Med. 1998;  158 157-161
    CrossrefPubMedGoogle Scholar
  • 49 Wendel K A, Alwood K S, Gachuhi R, Chaisson R E, Bishai W R, Sterling T R. Paradoxical worsening of tuberculosis in HIV-infected persons.  Chest. 2001;  120 193-197
    CrossrefPubMedGoogle Scholar
  • 50 CDC . Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations.  MMWR Morb Mortal Wkly Rep. 1998;  47(RR-20)
    PubMedGoogle Scholar
  • 51 Dean G L, Edwards S G, Ives N J et al.. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.  AIDS. 2002;  16 75-83
    PubMedGoogle Scholar
  • 52 Burman W, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of HIV-related tuberculosis.  Clin Infect Dis. 1999;  28 419-430
    PubMedGoogle Scholar
  • 53 CDC . Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors.  MMWR Morb Mortal Wkly Rep. 2000;  49 185-189
    PubMedGoogle Scholar
  • 54 Burman W J, Jones B E. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy.  Am J Respir Crit Care Med. 2001;  164 7-12
    PubMedGoogle Scholar
  • 55 Moreno S, Podzamczer D, Blazquez R et al.. Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin.  AIDS. 2001;  15 1185-1187
    CrossrefPubMedGoogle Scholar
  • 56 Lopez-Cortes L, Ruiz-Valderas R, Viciana P et al.. Pharmacokinetic interactions between efavirenz andrifampin in HIV-infected patients with tuberculosis.  Clin Pharmacokinet. 2002;  41 681-690
    PubMedGoogle Scholar
  • 57 Veldkamp A, Hoetelmans R, Beijnen J H, Mulder J W, Meenhorst P L. Ritonavir enables combined therapy with rifampin and saquinavir.  Clin Infect Dis. 1999;  29 1586
    CrossrefPubMedGoogle Scholar
  • 58 Ribera E, Pou L, Lopez R M et al.. Pharmacokinetic interaction between nevaripine and rifampicin in HIV-infected patients with tuberculsis.  J Acquir Immune Defic Syndr. 2001;  28 450-453
    CrossrefPubMedGoogle Scholar
  • 59 Nunn P, Kibuga D, Gathua S et al.. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis.  Lancet. 1991;  337 627-630
    PubMedGoogle Scholar
  • 60 Jindani A. IUATLD Clinical Trials Programme Study A (8 months versus 6 months treatment): Initial Results. Paper presented at American Thoracic Society 99th International Conference May 2003 American Thoracic Society New York;
    Google Scholar
  • 61 Hargreaves N J, Kadzakumanja O, Whitty C JM, Salaniponi F ML, Harries A D, Squire S B. Smear-negative pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence.  Int J Tuberc Lung Dis. 2001;  5 847-854
    PubMedGoogle Scholar
  • 62 Connolly C, Davies G R, Wilkinson D. Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991-1995.  Int J Tuberc Lung Dis. 1998;  2 919-925
    PubMedGoogle Scholar
  • 63 Joint United Nations Programme on HIV/AIDS .Provisional recommendations on the use of cotrimoxazole as part of a minimum package of care in adults and children living with HIV/AIDS in Africa. Available at: http://www.unaids.org/whatsnew/press/eng/pressarc00/recosummary.doc. Accessed October 22, 2003
    Google Scholar
  • 64 Markowitz N, Hansen N I, Wilcosky T C et al.. Tuberculin and anergy testing in HIV-seropositive persons.  Ann Intern Med. 1993;  119 185-193
    CrossrefPubMedGoogle Scholar
  • 65 Huebner R E, Schein M F, Hall C A, Barnes S A. Delayed-type hypersensitivity anergy in human immunodeficiency virus-infected persons screened for infection with Mycobacterium tuberculosis .  Clin Infect Dis. 1994;  19 26-32
    PubMedGoogle Scholar
  • 66 Center for Disease Control . Anergy skin testing and preventive therapy for HIV-infected persons.  MMWR Morb Mortal Wkly Rep. 1997;  46
    PubMedGoogle Scholar
  • 67 WHO Global Tuberculosis Programme and Global Programme on Vaccines . Statement on BCG revaccination for the prevention of tuberculosis.  Wkly Epidemiol Rec. 1995;  70 229-231
    PubMedGoogle Scholar
  • 68 Lifschitz M. The value of the tuberculin skin test as a screening test for tuberculosis among BCG-vaccinated children.  Pediatrics. 1965;  36 624-627
    PubMedGoogle Scholar
  • 69 Menzies R I, Vissandjee B. Effect of bacilli Calmette-Guerin vaccination on tuberculin reactivity.  Am Rev Respir Dis. 1992;  145 621-625
    PubMedGoogle Scholar
  • 70 WHO . Preventive therapy against tuberculosis in people living with HIV.  Wkly Epidemiol Rec. 1999;  46 385-397
    PubMedGoogle Scholar
  • 71 Markowitz N, Hansen N I, Hopewell P C et al.. Incidence of tuberculosis in the United States among HIV-infected persons.  Ann Intern Med. 1997;  126 123-132
    CrossrefPubMedGoogle Scholar
  • 72 Desormeaux J, Johnson M P, Coberly J S et al.. Widespread HIV counseling and testing linked to a community-based tuberculosis control program in a high-risk population.  Bull Pan Am Health Org. 1996;  30 1-8
    PubMedGoogle Scholar
  • 73 Available at: http://www.who.int/gtb/TBHIV/Durban_feb03/index.htm. Accessed October 22, 2003
  • 74 Godfrey-Faussett P, Maher D, Mukadi Y O, Nunn P, Perriens J, Raviglione M. How human immunodeficiency virus voluntary testing can contribute to tuberculosis control.  Bull World Health Organ. 2002;  80 939-945
    PubMedGoogle Scholar
  • 75 World Health Organization .Interim Policy on Collaborative TB/HIV Activities. Geneva; World Health Organization 2003
    Google Scholar
  • 76 Available at: http://www.who.int/mediacentre/factsheets/2003/fs274/en. Accessed October 22, 2003

Naomi BockM.D. M.S. 

Global AIDS Program, Centers for Disease Control and Prevention

1600 Clifton Rd., Mail Stop E-04

Atlanta, GA 30333

Email: nbock@cdc.gov

      >